利妥昔单抗联合化疗治疗复发B细胞恶性淋巴瘤的回顾性分析  

The Effect of Ritumaxib Combined with Chemotherapy on Relapsed B Cell Lymphoma

作　　者：杜芹[1] 杨锡贵[1] 

机构地区：[1]山东省肿瘤防治研究院

出　　处：《中国肿瘤临床》2009年第4期203-206,共4页Chinese Journal of Clinical Oncology

摘　　要：目的：探讨含利妥昔单抗（关罗华）方案在复发B细胞性淋巴瘤治疗中的效果，同时分析影响疗效的相关因素。方法：回顾性总结我院用利妥昔单抗单药或联合化疗对复发B细胞恶性淋巴瘤患者的疗效及不良反应和影响因素。结果：20例可评价疗效的患者中2例用利妥昔单抗单药，弄，3妥昔单抗联合化疗者18例，总有效率（RR）70％（14／20），完全缓解率（CR）20％（4／20）。中位总生存期是17．5个月，1年、2年及3年的总生存率分别是68％、45％和32％；中位无进展生存期是11．5个月，1、2、3年的无进展生存率分别是55％、32％和23％。疗效与临床分期、IPI评分、结外侵犯有关，与其他因素无明显相关。输注利妥昔单抗后主要不良反应为畏寒、发热、乏力等输注相关反应。结论：利妥昔单抗应用于复发B细胞性淋巴瘤疗效高，不良反应可以耐受。Objective： To evaluate the efficacy and safety of rituximab-containing regimen for treating re- lapsed B cell lymphoma, and to analyze the influential factors for patient response. Methods： We reviewed the clinical data of patients with relapsed B cell lymphoma who received infusions of rituximab combined with or without chemotherapy in our hospital. The influence of age, clinical stage, and international prognostic index （IPI） score on response was evaluated. Results： Of the 20 evaluable patients, 2 received rituximab alone, and the other 18 received rituximab-containing regimens. The objective response rate was 70% （14/20）, with a complete remission （CR） rate of 20% （4/20）. The median overall survival was 17.5 months. The overall 1-, 2-, and 3-year survival rates were 68%, 45%, and 32%, respectively. The median progression-free survival was 11.5 months. The progression-free 1-, 2-, and 3-year survival rates were 55%, 32%, and 23%, respectively. Ef- ficacy was related to clinical stage, IPI score, extranodal involvement and lesion diameter. The main adverse events after rituximab infusion were infusion-related reactions such as chills, fever and debilitation. Conclusion： Rituximab-containing regimen is effective and well tolerated for patients with relapsed B-cell lymphoma.

关 键 词：利妥昔单抗 非霍奇金淋巴瘤/化学疗法 挽救治疗 

分 类 号：R733.1[医药卫生—肿瘤]